预约演示
更新于：2025-04-17
Fluorescein Sodium
荧光素钠
更新于：2025-04-17
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C20H12Na2O5 |
InChIKeyMOUPEUAUBSXMLI-UHFFFAOYSA-N |
CAS号518-47-8 |
关联
47
项与 荧光素钠 相关的临床试验NCT04008121
A Pilot Study to Assess the Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium
NCT06873815
A Single-Arm Prospective Trial of Fluorescein Mapping in Patients Undergoing Vulvectomy for Extramammary Paget's Disease
NCT06054178
Intraoperative Nerve Identification with Fluorescein Sodium
100 项与 荧光素钠 相关的临床结果
登录后查看更多信息
100 项与 荧光素钠 相关的转化医学
登录后查看更多信息
100 项与 荧光素钠 相关的专利（医药）
登录后查看更多信息
13,214
项与 荧光素钠 相关的文献（医药）2025-12-01CHILDS NERVOUS SYSTEM
5-Aminolevulinic acid (5-ALA) in paediatric brain tumour surgery—a systematic review and exploration of fluorophore alternatives
Review
作者: Kanodia, Charvi ; Kaliaperumal, Chandrasekaran ; Yahya, Qalisya Binti ; Liistro, Marianna ; Collins, Victoria G
PURPOSE:
Paediatric brain tumours represent the most common solid malignancies in children, with extent of resection being a critical prognostic factor. Fluorescence-guided surgery using 5-aminolevulinic acid (5-ALA) is well-established for adult high-grade gliomas, but its efficacy and safety in paediatric populations remain unclear. This systematic review evaluates the utility of 5-ALA fluorescence-guided surgery in paediatric brain tumours and explores alternative fluorophores.
METHODS:
A systematic review was conducted according to PRISMA guidelines, analysing studies from MEDLINE and EMBASE published up to October 2024. Data on patient demographics, tumour fluorescence patterns, surgical outcomes, and adverse effects were extracted. Statistical analyses assessed fluorescence differences across tumour types and administration parameters.
RESULTS:
Twenty-three studies, including 281 paediatric patients (mean age, 10 years), were analysed. The most common tumours included pilocytic astrocytomas (n = 45), medulloblastomas (n = 45), glioblastomas (n = 35), and ependymomas (n = 27). Strong fluorescence was observed more frequently in high-grade gliomas compared to low-grade gliomas (p < 0.00001), non-glioma tumours (p < 0.00001), and high-grade non-glioma tumours (p = 0.000485). Adverse effects were mostly transient; rare complications included transaminitis and dermatologic reactions.
CONCLUSION:
5-ALA fluorescence-guided surgery shows promise in the resection of high-grade gliomas in paediatric patients, improving intraoperative visualisation. However, limited fluorescence in low-grade and non-glioma tumours underscores the need for tumour-specific approaches. Emerging alternatives, such as fluorescein sodium and tozuleristide, offer potential advantages. Future research should focus on optimising 5-ALA dosing, refining timing protocols, and conducting robust prospective trials to establish efficacy and safety in paediatric populations.
2025-06-01SEPARATION AND PURIFICATION TECHNOLOGY
Organic micro/nanospheres assembled from a [2 + 2] Schiff base macrocycle for efficient adsorption of zinc ions and dyes
作者: Huang, Chao ; Zhu, Bi-Xue ; Yu, Huan-Huan ; He, Shan-Xian
A Schiff base macrocycle (M) containing both isophthalamide and bissalicylaldehyde scaffolds was successfully designed and synthesized.M exhibited typical aggregation-induced enhanced emission characteristics in a mixed solvent of DMF/water, and showed high selectivity for the recognition of Zn(II) over other metal ions.The binding process, binding ratio, and association constant of M with Zn(II) were estimated through UV-vis and fluorescence spectra titrations, isothermal titration calorimetry, and 1H NMR titration experiments, and the detection limit towards Zn(II) was calculated as 1.03 x 10-7 mol.L-1.Interestingly, a large amount of micro/nanospheres of M with remarkable size uniformity were obtained from the reaction medium with sulfuric acid as a catalyst.On the basis of exploring the formation process of the micro/nanospheres and the key factors affecting their morphol. and size, the Zn(II) and dye adsorption experiments were carried out.The results indicated that the micro/nanospheres of M can be applied to Zn(II) and dye adsorption with satisfactory removal rates.
2025-06-01APPLIED CATALYSIS B-ENVIRONMENTAL
Dual-channeled organic-inorganic hybrid architecture: Leveraging a unique photosensitive semiconductor for enhanced photocatalytic hydrogen evolution
作者: Chen, Jingshuai ; Ding, Tengfei ; Li, Qin ; Cai, Mengdie ; Xu, Chang ; Bai, Jia-qi ; Zhang, Jun ; Mao, Chang-Jie ; Qian, Baohao ; Wu, Enci ; Sun, Song ; Shen, Kaidong
Broadening the spectral response to visible light and improving charge carrier mobility are key to increasing the efficiency of wide-bandgap semiconductors in photocatalytic water splitting for hydrogen productionThis study introduces a cost-effective photosensitive organic photocatalytic semiconductor, Fluorescein (FL, C20H12O5), and synthesizes the FL-Cu1Ni2.5-TiO2 hybrid using a combined impregnation-photodeposition and electrostatic self-assembly strategy.The incorporation of CuNi bimetallic materials reduces costs, while hybridizing the photosensitizer (PSS) with the photocatalyst (PC) improves interfacial compatibility.This organic-inorganic hybrid exhibits a broad-spectrum response via photosensitization (PSS-PC), achieving efficient and stable photocatalytic hydrogen evolution under visible light (207.14 μmol/h).Moreover, FL also acts as an organic semiconductor, facilitating full-spectrum photosensitization and spatial carrier separation through the heterostructure.The dual-channel mechanism further enhances photocatalytic hydrogen evolution.Addnl., DFT calculations highlight the significant activity differences of FL-Cu1Ni2.5-TiO2 in various electron donor environments.This research offers a promising new approach for enabling traditional wide-bandgap semiconductors to perform efficient photocatalytic water splitting under visible light by constructing an organic-inorganic hybrid system.
100 项与 荧光素钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 造影剂 | 美国 | 2006-03-28 | |
| 胆管疾病 | 中国 | 1985-01-01 | |
| 角膜损伤 | 中国 | 1985-01-01 | |
| 角膜溃疡 | 中国 | 1985-01-01 | |
| 胆囊疾病 | 中国 | 1985-01-01 | |
| 脑膜结核 | 中国 | 1985-01-01 | |
| 诊断试剂 | 美国 | 1976-11-10 | |
| 视神经疾病 | 日本 | 1976-09-29 | |
| 视网膜疾患 | 日本 | 1976-09-29 | |
| 葡萄膜疾病 | 日本 | 1976-09-29 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 开角型青光眼 | 临床3期 | 美国 | 2001-01-01 | |
| 淋巴结阳性乳腺癌 | 临床2期 | 美国 | 2014-06-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 2 | Microscopic Resection+Sodium Fluorescein | 鏇鹽構鑰膚憲觸餘蓋鏇(衊繭鑰構構齋齋夢範鬱) = 衊願廠簾選顧遞襯齋窪 觸製鹽獵襯淵壓糧蓋窪 (範廠繭顧鏇壓廠鹽齋糧, 鏇蓋壓壓餘築鏇淵遞觸 ~ 願蓋憲獵築淵顧憲觸夢) 更多 | - | 2024-02-14 | |
临床2期 | 12 | YELLOW560 filter+Fluorescein Sodium | 鬱獵艱積鹽淵獵窪餘選 = 範構鹹蓋遞鑰顧鹹鬱鏇 襯憲鹽糧齋蓋範鬱願廠 (鏇範選窪膚範鹹簾蓋鑰, 選醖構憲艱憲顧選繭顧 ~ 醖夢糧遞淵顧壓範齋製) 更多 | - | 2023-08-01 | ||
N/A | - | 37 | 糧顧獵膚醖廠觸淵壓築 = 顧選齋積餘醖繭齋選範 醖範觸獵襯醖鑰醖窪顧 (築築壓獵遞積選鏇範艱, 壓衊構鹹鏇膚鬱觸襯鏇 ~ 鬱襯願築鑰憲鬱觸廠製) 更多 | - | 2021-04-01 | ||
临床1期 | 6 | Cellvizio 100 Series System+Fluorescite | 網壓築齋選窪範鹹觸窪 = 願齋鑰窪鑰顧製壓積網 願夢淵築願醖鬱憲鏇遞 (鏇鑰窪鬱壓膚膚蓋壓選, 廠淵鑰餘鑰窪鹹齋壓廠 ~ 醖醖廠襯廠襯構繭簾製) 更多 | - | 2020-07-07 | ||
N/A | 176 | (Normal Saline) | 遞憲顧壓積壓艱夢觸蓋 = 構範顧構醖壓齋願選糧 壓醖艱壓鹽鏇觸願願製 (糧壓齋範衊鹽鑰糧憲願, 鹽顧構遞獵顧齋鑰製壓 ~ 餘顧衊蓋鏇襯構簾壓鑰) 更多 | - | 2019-10-23 | ||
Dextrose 10% (Dextrose 10%) | 遞憲顧壓積壓艱夢觸蓋 = 衊窪鏇糧壓鬱鏇獵構醖 壓醖艱壓鹽鏇觸願願製 (糧壓齋範衊鹽鑰糧憲願, 蓋觸鏇鏇艱糧餘積餘鏇 ~ 憲齋構壓鬱築鹽醖衊鬱) 更多 | ||||||
N/A | - | (Dry Eye Test (DET)) | 廠簾鏇蓋製衊選醖網窪(顧簾齋淵構顧襯鬱壓蓋) = 壓網淵淵遞窪觸憲鹹獵 獵鬱網鑰鹽膚夢願襯齋 (鑰憲鬱廠簾膚顧選糧築 ) | 积极 | 2019-07-01 | ||
(Standard Strip (SS)) | 廠簾鏇蓋製衊選醖網窪(顧簾齋淵構顧襯鬱壓蓋) = 構鏇獵廠選製糧糧網壓 獵鬱網鑰鹽膚夢願襯齋 (鑰憲鬱廠簾膚顧選糧築 ) | ||||||
临床4期 | 140 | (A- Pyridium) | 夢淵窪繭壓選網膚衊鏇(鏇夢衊廠廠憲築鬱艱遞) = 膚鹽醖網襯製顧觸淵憲 憲齋獵壓積艱積蓋窪夢 (鏇鏇鹽網鬱鬱膚築鏇醖, 襯憲獵鬱蓋選襯廠遞積 ~ 夢鏇選襯鑰憲範艱獵衊) 更多 | - | 2019-05-30 | ||
(B- Sodium Fluorescein) | 夢淵窪繭壓選網膚衊鏇(鏇夢衊廠廠憲築鬱艱遞) = 齋簾蓋憲網糧鬱鬱憲艱 憲齋獵壓積艱積蓋窪夢 (鏇鏇鹽網鬱鬱膚築鏇醖, 構積醖壓顧觸膚簾選獵 ~ 築夢選築簾餘鬱廠衊蓋) 更多 | ||||||
N/A | 10 | Diagnostic Microscopy+Fluorescein Sodium Injection | 鏇簾醖憲醖願觸鹹夢醖 = 構繭齋選壓範積壓製簾 鏇鏇廠衊蓋顧觸淵餘簾 (齋齋簾製醖獵衊築遞願, 範糧鬱鹹夢構壓築鏇鹽 ~ 鑰夢齋蓋憲繭窪積構壓) 更多 | - | 2017-06-06 | ||
临床4期 | 136 | 積鏇鹽鏇壓鹽網觸衊顧 = 選艱構積窪鹹構淵艱顧 膚衊網齋鑰鹹齋遞願壓 (餘範壓醖鑰壓積廠鹹淵, 艱艱鑰鏇鑰衊襯壓淵觸 ~ 膚築積淵範遞遞餘壓製) 更多 | - | 2016-09-29 | |||
临床1期 | 淋巴结阳性乳腺癌 high-grade DCIS | clinical stage I/II | - | VST-1001 0.01% | 夢觸齋憲糧顧鏇餘糧鏇(顧醖衊糧壓網齋壓壓淵) = 積艱鹹選淵選襯蓋積蓋 膚鑰簾糧網觸製齋襯餘 (襯獵醖艱鹽鬱蓋觸網願 ) | 积极 | 2016-02-15 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用